MARKET

PYXS

PYXS

Pyxis Oncology, Inc.
NASDAQ
2.900
0.000
0.00%
Opening 14:21 09/29 EDT
OPEN
2.940
PREV CLOSE
2.900
HIGH
2.940
LOW
2.830
VOLUME
105.29K
TURNOVER
--
52 WEEK HIGH
5.55
52 WEEK LOW
1.030
MARKET CAP
241.88M
P/E (TTM)
-2.0688
1D
5D
1M
3M
1Y
5Y
1D
Pyxis Oncology announces common stock offering, no amount given
TipRanks · 4h ago
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed
Benzinga · 4h ago
Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
Benzinga · 4h ago
Weekly Report: what happened at PYXS last week (0921-0925)?
Weekly Report · 1d ago
LifeSci Capital Remains a Buy on Pyxis Oncology (PYXS)
TipRanks · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)
TipRanks · 09/22 13:30
Weekly Report: what happened at PYXS last week (0914-0918)?
Weekly Report · 09/21 09:21
Pyxis Oncology: MICVO’s Emerging Clinical Profile and Strong Physician Receptivity Support Buy Rating and Unchanged $6 Price Target
TipRanks · 09/16 21:57
More
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Webull offers Pyxis Oncology Inc stock information, including NASDAQ: PYXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PYXS stock methods without spending real money on the virtual paper trading platform.